ipilimumab,nivolumab,Dabrafenib,Trametinib
bms,novartis
['melanoma']
#asco22 #chicago live update by mike atkins on the landmark dreamseq #immunotherapy #targeted therapy sequencing trial in #melanoma 
Professor, Senior Member, Director Cutaneous Clinical & Translational Research @MoffittResearch @MoffittNews @USouthFlorida / Tweets are mine